Home › All Companies › CLDWW › Annual Report

Calidi Biotherapeutics, Inc. (CLDWW) — Annual Report

AI-Powered SEC Filing Analysis

← All CLDWW filings
Latest Annual Report Filed: 2026-03-27

Key Insights

  • The company's financial results and key operating metrics for fiscal years 2024 and 2025 appear to be disclosed, providing investors insight into its recent performance.
  • The filing mentions various equity-based compensation arrangements, such as warrants, stock options, and restricted stock units, which could impact the company's capital structure and shareholder dilution.
  • The company has received government grants, including from the California Institute for Regenerative Medicine, which may indicate progress in its research and development efforts.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Calidi Biotherapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.